Spyre Therapeutics (SYRE) said late Wednesday it closed its public offering of about 17.1 million common shares, including the full exercise of underwriters' overallotment option to buy 2.2 million shares, for gross proceeds of roughly $316.2 million.

The shares were sold at $18.50 each, the company said.